Comparison of the effects of salmeterol and formoterol in patients with severe asthma

Chest

Volumn 121, Issue 5, 2002, Pages 1401-1406

  Nightingale, Julia A ^a   Rogers, Duncan F ^a   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Formoterol; Salmeterol; Severe asthma

Indexed keywords

CORTICOSTEROID; FORMOTEROL; PLACEBO; SALMETEROL;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; SCORING SYSTEM; SPIROMETRY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036257390     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.5.1401     Document Type: Article

References (31)

1. β-adrenergic bronchodilators
2. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours
3. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic
4. 2-agonist formoterol
5. Asthma in adults and schoolchildren
6. 2-agonist, inhaled twice daily, in stable asthmatic subjects
7. Inhaled salmeterol and salbutamol in asthmatic patients: An evaluation of asthma symptoms and the possible development of tachyphylaxis
8. Salmeterol: A four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease
9. Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro
10. 2-agonists: Eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics
11. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease
12. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
13. Pharmacological basis for duration of effect: Formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists
14. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus
15. Inhaled dry powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency
16. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction
17. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma
18. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients
19. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airways disease
20. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma
21. Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids
22. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol
23. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma
24. Salmeterol xinofoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy
25. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids
26. Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids
27. The beta 2-agonist controversy: Observations, explanations and relationship to asthma epidemiology
28. Addition of leukotriene antagonists to therapy in chronic persistent asthma: A randomised double-blind placebo-controlled trial
29. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma
30. Effect of inhaled formoterol and budesonide on exacerbations of asthma